Back

BioGend revenue rises 14.22% to NT$114 million in first half 2026

Verifying
  • BioGend presented first-half 2026 results at Dacin Securities' institutional investor conference.
  • NT$114 million revenue rose 14.22% year-over-year; post-tax loss reached NT$39.706 million.
  • RevoCart and critical infection products will drive growth while BioGend remains loss-making this year.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.